Apellis hopes to meet you in our booth, #409!
With courageous science, creativity, and compassion, Apellis is committed to developing therapies for people with complement-driven diseases.
Our work is focused on C3, the central protein of the complement cascade and the only target that addresses all three activation pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available.
©2021 Apellis Pharmaceuticals, Inc. All rights reserved. 8/21 US-CORP-2100028 v1.0